Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4
about
Acute and Chronic Cutaneous Reactions to Ionizing Radiation TherapyProtecting the radiation-damaged skin from friction: a mini reviewPrevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trialsAcute radiation dermatitis in breast cancer patients: challenges and solutionsVitamin D ointment for prevention of radiation dermatitis in breast cancer patients.Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Photobiomodulation for the management of radiation dermatitis: the DERMIS trial, a pilot study of MLS(®) laser therapy in breast cancer patients.Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4).Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).Prophylactic Treatment with Adlay Bran Extract Reduces the Risk of Severe Acute Radiation Dermatitis: A Prospective, Randomized, Double-Blind StudyDermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy.Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy.Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.Topical agent therapy for prevention and treatment of radiodermatitis: a meta-analysis.Topical corticosteroid therapy for the prevention of acute radiation dermatitis: a systematic review of randomized controlled trials.Radiodermatitis: A Review of Our Current Understanding.Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]).Complementary and alternative medicine in reducing radiation-induced skin toxicity.Complete prevention of radiation-induced dermatitis using topical adrenergic vasoconstrictors.A randomized, double-blind trial on the use of 1% hydrocortisone cream for the prevention of acute radiation dermatitis.Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191-2200.Radiotherapy for a breast cancer patient with Schnitzler syndrome: Report of acute toxicity and early follow-up.Late cutaneous effects of a local potent steroid during adjuvant radiotherapy for breast cancer.The incidence of postoperative radiotherapy-induced acute dermatitis in breast cancer and its influencing factors for Chinese women.Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial
P2860
Q26744148-50AE6F2A-62CB-47BA-9368-93373E85FE5BQ28265714-84466CA0-36C8-492D-81DB-77ECEA265030Q31149109-FABFAB70-CD8F-44E7-A1FB-176AB4F93E11Q33662782-A1672CBC-DC3F-44B8-B6B3-01116F824748Q33767299-78138175-7B86-4540-AEB3-1745013DBDA8Q34940071-998F693E-485E-4483-B869-354E19732164Q35083960-1EF515F6-F408-4CC7-9281-4A3A0193194AQ35999596-00CA7BAE-D864-4FF7-B293-4BBABEF5B83CQ36002272-A48615EB-F0CE-4879-B510-034574DDCDE1Q36080860-BAF36960-2A37-4395-B433-7EE212556913Q36162749-8DE77763-F04E-4681-B0FB-8AC7C8FB4F31Q36246406-386E04A1-73CD-44A0-930F-0D522F03D80DQ37175665-FC33A0F2-3997-443A-A8BE-E38D01AC567AQ37565556-7F434166-5795-4280-AA20-6081FD87A1B8Q37624254-D1B30399-28DC-4F5B-95A2-BA91DC59719AQ38052024-327F3649-C1AC-44BB-986F-8A9FAFAEADD5Q38155931-DC7CCDCE-5EC0-4BE0-8997-09EDF4185C3AQ38791798-71C1F147-446D-4080-8B9F-E5494C923306Q38881581-55E38EEE-C5E6-41AB-A08E-ED6656A50D0AQ39199358-E0AAB387-554D-48E4-86C6-8C34067DF053Q39322076-4F8F2E8A-1F2C-4BFB-9DD9-B6F5143DE2CDQ41087561-E0768B5D-E95A-4DAA-8B8A-A8E9866B5A38Q47904447-444CD7F3-E836-49AF-A0A0-C3C1D8056EC2Q49979072-42F709CB-6FDF-4E50-8F9A-33759248EB29Q55182805-B792E648-6185-4697-A902-FA182AD90ED8Q55365327-B4B4022E-90D4-461B-A9F5-29F682181255Q58761794-F4275042-BBE3-4E18-8E63-DCA2C2945845
P2860
Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@ast
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@en
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@nl
type
label
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@ast
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@en
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@nl
prefLabel
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@ast
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@en
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@nl
P2093
P2860
P1476
Mometasone furoate effect on a ...... l Cancer Treatment Group N06C4
@en
P2093
Charles L Loprinzi
James A Martenson
James D Bearden
Jeff A Sloan
Jon C Anders
Pamela J Atherton
Patricia C Griffin
Paul L Schaefer
Richard L Deming
Robert E Haselow
P2860
P304
P356
10.1016/J.IJROBP.2010.01.031
P407
P577
2010-08-26T00:00:00Z